RxDoctor Payments DataLook up a doctor →

Timothy You, MD

Ophthalmology · Santa Ana, CANPI 1326041880

Payments from drug & device makers

$608,399in general payments, 2019–2025

Across 584 payments — averaging $1041.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Apellis Pharmaceuticals, Inc.$253K
  • Topcon Healthcare Solutions, Inc.$176K
  • Topcon Healthcare, Inc.$117K
  • Bausch & Lomb Americas Inc.$16K
  • Genentech USA, Inc.$13K
  • AbbVie$10K
  • plus $24K from 31 others

What the payments were for

  • Consulting fees$27,89051%
  • Speaking & faculty fees$8,32315%
  • Travel & lodging$1,4493%
  • Food & beverage$16,87231%
  • Education$180%
  • Entertainment$2891%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$608,399 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$4,611,195
Medicare patients
1,860
Services billed
78,241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine59$50,962
SimbrinzaBrinzolamide/Brimonidine Tart99$20,179
XiidraLifitegrast14$15,313
Prednisolone Acetate414$13,940
Cyclosporine33$13,788
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol93$11,857
Alphagan PBrimonidine Tartrate24$11,844
RhopressaNetarsudil Mesylate21$8,474
LumiganBimatoprost18$7,820
Loteprednol Etabonate45$7,635
CombiganBrimonidine Tartrate/Timolol20$4,660
Brimonidine Tartrate141$3,001
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat101$1,493
Atropine Sulfate39$1,336
MoxifloxacinMoxifloxacin Hcl59$1,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Lumigan, Combigan$10,380$75,287121 claims
AlconSimbrinza$3,341$20,17999 claims
Bausch & Lomb Americas Inc.Xiidra$15,524$15,31314 claims
Aerie Pharmaceuticals, Inc.Rhopressa$298$8,47421 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Santa Ana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →